Amifampridine (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Amifampridine" in English language version.

refsWebsite

Global rank English rank

20nih.gov

4^th place

15doi.org

2^nd place

6web.archive.org

1^st place

6semanticscholar.org

11^th place

8^th place

5fda.gov

447^th place

338^th place

3europa.eu

68^th place

117^th place

3bizjournals.com

407^th place

241^st place

3harvard.edu

18^th place

17^th place

2tga.gov.au

3,984^th place

2,622^nd place

2hres.ca

low place

2nytimes.com

7^th place

2fiercebiotech.com

low place

8,828^th place

2nbcnews.com

137^th place

101^st place

1england.nhs.uk

low place

1sciencemag.org

857^th place

3,832^nd place

1statnews.com

8,771^st place

5,253^rd place

1yixiblog.wordpress.com

low place

1pemagazine.fr

low place

1pharmaceutical-technology.com

low place

1bbc.com

20^th place

30^th place

1who.int

195^th place

302^nd place

1mda.org

low place

1raredr.com

low place

1drugs.com

399^th place

333^rd place

1cnn.com

28^th place

26^th place

bbc.com

Goldberg A (November 21, 2010). "Drug firms accused of exploiting loophole for profit". BBC News.

bizjournals.com

"BioMarin licenses North American rights to rare disease drug, invests $5M in Florida company". www.bizjournals.com. Retrieved December 17, 2019.
Leuty R (October 31, 2012). "BioMarin licenses North American rights to rare disease drug, invests $5M in Florida company". San Francisco Business Journal.
Lima D (March 29, 2018). "Catalyst Pharmaceuticals files new drug application with FDA". South Florida Business Journal.

cnn.com

edition.cnn.com

Drash W (May 8, 2019). "FDA undercuts $375,000 drug in surprise move". CNN Health. Retrieved May 12, 2019.

doi.org

Argov Z (October 2009). "Management of myasthenic conditions: nonimmune issues". Current Opinion in Neurology. 22 (5): 493–497. doi:10.1097/WCO.0b013e32832f15fa. PMID 19593127. S2CID 10408557.
Keogh M, Sedehizadeh S, Maddison P (February 2011). "Treatment for Lambert-Eaton myasthenic syndrome". The Cochrane Database of Systematic Reviews. 2011 (2): CD003279. doi:10.1002/14651858.CD003279.pub3. PMC 7003613. PMID 21328260.
Tarr TB, Wipf P, Meriney SD (August 2015). "Synaptic Pathophysiology and Treatment of Lambert-Eaton Myasthenic Syndrome". Molecular Neurobiology. 52 (1): 456–463. doi:10.1007/s12035-014-8887-2. PMC 4362862. PMID 25195700.
Kirsch GE, Narahashi T (June 1978). "3,4-diaminopyridine. A potent new potassium channel blocker". Biophysical Journal. 22 (3): 507–512. Bibcode:1978BpJ....22..507K. doi:10.1016/s0006-3495(78)85503-9. PMC 1473482. PMID 667299.
Rubin-Preminger JM, Englert U (2007). "3,4-Diaminopyridine". Acta Crystallographica Section E. 63 (2): o757–o758. Bibcode:2007AcCrE..63O.757R. doi:10.1107/S1600536807001444.
Mahé N, Nicolaï B, Allouchi H, Barrio M, Do B, Céolin R, et al. (2013). "Crystal Structure and Solid-State Properties of 3,4-Diaminopyridine Dihydrogen Phosphate and Their Comparison with Other Diaminopyridine Salts". Cryst Growth Des. 13 (2): 708–715. doi:10.1021/cg3014249.
Drummond M, Towse A (May 2014). "Orphan drugs policies: a suitable case for treatment". The European Journal of Health Economics. 15 (4): 335–340. doi:10.1007/s10198-014-0560-1. PMID 24435513.
Nicholl DJ, Hilton-Jones D, Palace J, Richmond S, Finlayson S, Winer J, et al. (November 2010). "Open letter to prime minister David Cameron and health secretary Andrew Lansley". BMJ. 341: c6466. doi:10.1136/bmj.c6466. PMID 21081599. S2CID 24929143.
Hawkes N, Cohen D (November 2010). "What makes an orphan drug?". BMJ. 341: c6459. doi:10.1136/bmj.c6459. PMID 21081607. S2CID 2486975.
Vedeler CA, Antoine JC, Giometto B, Graus F, Grisold W, Hart IK, et al. (July 2006). "Management of paraneoplastic neurological syndromes: report of an EFNS Task Force". European Journal of Neurology. 13 (7): 682–690. doi:10.1111/j.1468-1331.2006.01266.x. PMID 16834698. S2CID 27161239.
Baker DE (November 2013). "Breakthrough Drug Approval Process and Postmarketing ADR Reporting". Hospital Pharmacy. 48 (10): 796–798. doi:10.1310/hpj4810-796. PMC 3859287. PMID 24421428.
Burns TM, Smith GA, Allen JA, Amato AA, Arnold WD, Barohn R, et al. (February 2016). "Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine". Muscle & Nerve. 53 (2): 165–168. doi:10.1002/mus.25009. PMID 26662952. S2CID 46855617.
McEnany PJ (January 2017). "A response to a recent editorial by concerned physicians on 3,4-diaminopyridine". Muscle & Nerve. 55 (1): 138. doi:10.1002/mus.25437. PMID 27756108.
Solari A, Uitdehaag B, Giuliani G, Pucci E, Taus C (2002). "Aminopyridines for symptomatic treatment in multiple sclerosis". The Cochrane Database of Systematic Reviews (4): CD001330. doi:10.1002/14651858.CD001330. PMC 7047571. PMID 12804404.
Sedehizadeh S, Keogh M, Maddison P (2012). "The use of aminopyridines in neurological disorders". Clinical Neuropharmacology. 35 (4): 191–200. doi:10.1097/WNF.0b013e31825a68c5. PMID 22805230. S2CID 41532252.

drugs.com

"Firdapse (amifampridine phosphate) FDA Approval History". Drugs.com. Retrieved February 5, 2019.

england.nhs.uk

engage.england.nhs.uk

"Evidence Review: Amifampridine phosphate for the treatment of Lambert–Easton Myasthenic Syndrome" (PDF). NHS England. December 2015.

europa.eu

ema.europa.eu

"Firdapse Summary of Product Characteristics" (PDF). EMA. February 11, 2010. Archived from the original (PDF) on June 20, 2018. Retrieved November 28, 2015. See EMA Index page, product tab Archived 2018-09-20 at the Wayback Machine
"Public summary of opinion on orphan designation" (PDF). EMA. June 14, 2010. Archived from the original (PDF) on June 21, 2018. Retrieved January 14, 2017.
"Assessment report: Zenas" (PDF). EMA CHMP committee. 2009. Archived from the original (PDF) on 2018-09-20. Retrieved 2015-05-28.

fda.gov

accessdata.fda.gov

"Orphan Drug Designations: amifampridine phosphate for congenital myasthenic syndromes". FDA. Retrieved January 14, 2017.
"Orphan Drug Designations: amifampridine phosphate for myasthenia gravis". www.accessdata.fda.gov. FDA. Retrieved January 14, 2017.
"Orrphan designation congenital myasthenic syndromes". FDA. Archived from the original on July 26, 2015.

fda.gov

"FDA approves first treatment for children with Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder". fda.gov. Retrieved 2019-05-11.
"Diaminopyridine (3,4-)" (PDF). FDA. Retrieved November 28, 2015.. Index page: FDA Docket 98N-0812: Bulk Drug Substances to be Used in Pharmacy Compounding

fiercebiotech.com

Adams B (April 26, 2016). "Catalyst Pharmaceuticals hit by FDA extra studies request for Firdapse". FierceBiotech.
Adams B (May 17, 2016). "Catalyst to ax 30% of workforce in wake of FDA trial demands". FierceBiotech.

harvard.edu

ui.adsabs.harvard.edu

Kirsch GE, Narahashi T (June 1978). "3,4-diaminopyridine. A potent new potassium channel blocker". Biophysical Journal. 22 (3): 507–512. Bibcode:1978BpJ....22..507K. doi:10.1016/s0006-3495(78)85503-9. PMC 1473482. PMID 667299.
Rubin-Preminger JM, Englert U (2007). "3,4-Diaminopyridine". Acta Crystallographica Section E. 63 (2): o757–o758. Bibcode:2007AcCrE..63O.757R. doi:10.1107/S1600536807001444.

blogs.harvard.edu

Deak D (February 22, 2016). "Jacobus and Catalyst Continue to Race for Approval of LEMS Drug". Bill of Health.

hres.ca

hpr-rps.hres.ca

"Summary Basis of Decision (SBD) for Firdapse". Health Canada. 23 October 2014. Retrieved 29 May 2022.
"Summary Basis of Decision (SBD) for Ruzurgi". Health Canada. 23 October 2014. Retrieved 29 May 2022.

mda.org

quest.mda.org

Wahl M (January 25, 2012). "Jacobus Begins Invitation-Only Trial of 3,4-DAP in LEMS". Muscular Dystrophy Association Quest Magazine Online.

nbcnews.com

"Bernie Sanders asks why drug, once free, now costs $375K". NBC News. 5 February 2019. Retrieved February 5, 2019.
"Family outraged over life-changing treatment going from free to $375,000 a year". NBC News. 8 February 2019.

nih.gov

pubmed.ncbi.nlm.nih.gov

Argov Z (October 2009). "Management of myasthenic conditions: nonimmune issues". Current Opinion in Neurology. 22 (5): 493–497. doi:10.1097/WCO.0b013e32832f15fa. PMID 19593127. S2CID 10408557.
Abicht A, Müller J, Lochmüller H (July 14, 2016). "Congenital Myasthenic Syndromes Overview". GeneReviews. University of Washington, Seattle. PMID 20301347.
Keogh M, Sedehizadeh S, Maddison P (February 2011). "Treatment for Lambert-Eaton myasthenic syndrome". The Cochrane Database of Systematic Reviews. 2011 (2): CD003279. doi:10.1002/14651858.CD003279.pub3. PMC 7003613. PMID 21328260.
Tarr TB, Wipf P, Meriney SD (August 2015). "Synaptic Pathophysiology and Treatment of Lambert-Eaton Myasthenic Syndrome". Molecular Neurobiology. 52 (1): 456–463. doi:10.1007/s12035-014-8887-2. PMC 4362862. PMID 25195700.
Kirsch GE, Narahashi T (June 1978). "3,4-diaminopyridine. A potent new potassium channel blocker". Biophysical Journal. 22 (3): 507–512. Bibcode:1978BpJ....22..507K. doi:10.1016/s0006-3495(78)85503-9. PMC 1473482. PMID 667299.
Drummond M, Towse A (May 2014). "Orphan drugs policies: a suitable case for treatment". The European Journal of Health Economics. 15 (4): 335–340. doi:10.1007/s10198-014-0560-1. PMID 24435513.
Nicholl DJ, Hilton-Jones D, Palace J, Richmond S, Finlayson S, Winer J, et al. (November 2010). "Open letter to prime minister David Cameron and health secretary Andrew Lansley". BMJ. 341: c6466. doi:10.1136/bmj.c6466. PMID 21081599. S2CID 24929143.
Hawkes N, Cohen D (November 2010). "What makes an orphan drug?". BMJ. 341: c6459. doi:10.1136/bmj.c6459. PMID 21081607. S2CID 2486975.
Vedeler CA, Antoine JC, Giometto B, Graus F, Grisold W, Hart IK, et al. (July 2006). "Management of paraneoplastic neurological syndromes: report of an EFNS Task Force". European Journal of Neurology. 13 (7): 682–690. doi:10.1111/j.1468-1331.2006.01266.x. PMID 16834698. S2CID 27161239.
Baker DE (November 2013). "Breakthrough Drug Approval Process and Postmarketing ADR Reporting". Hospital Pharmacy. 48 (10): 796–798. doi:10.1310/hpj4810-796. PMC 3859287. PMID 24421428.
Burns TM, Smith GA, Allen JA, Amato AA, Arnold WD, Barohn R, et al. (February 2016). "Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine". Muscle & Nerve. 53 (2): 165–168. doi:10.1002/mus.25009. PMID 26662952. S2CID 46855617.
McEnany PJ (January 2017). "A response to a recent editorial by concerned physicians on 3,4-diaminopyridine". Muscle & Nerve. 55 (1): 138. doi:10.1002/mus.25437. PMID 27756108.
Solari A, Uitdehaag B, Giuliani G, Pucci E, Taus C (2002). "Aminopyridines for symptomatic treatment in multiple sclerosis". The Cochrane Database of Systematic Reviews (4): CD001330. doi:10.1002/14651858.CD001330. PMC 7047571. PMID 12804404.
Sedehizadeh S, Keogh M, Maddison P (2012). "The use of aminopyridines in neurological disorders". Clinical Neuropharmacology. 35 (4): 191–200. doi:10.1097/WNF.0b013e31825a68c5. PMID 22805230. S2CID 41532252.

ncbi.nlm.nih.gov

Abicht A, Müller J, Lochmüller H (July 14, 2016). "Congenital Myasthenic Syndromes Overview". GeneReviews. University of Washington, Seattle. PMID 20301347.
Keogh M, Sedehizadeh S, Maddison P (February 2011). "Treatment for Lambert-Eaton myasthenic syndrome". The Cochrane Database of Systematic Reviews. 2011 (2): CD003279. doi:10.1002/14651858.CD003279.pub3. PMC 7003613. PMID 21328260.
Tarr TB, Wipf P, Meriney SD (August 2015). "Synaptic Pathophysiology and Treatment of Lambert-Eaton Myasthenic Syndrome". Molecular Neurobiology. 52 (1): 456–463. doi:10.1007/s12035-014-8887-2. PMC 4362862. PMID 25195700.
Kirsch GE, Narahashi T (June 1978). "3,4-diaminopyridine. A potent new potassium channel blocker". Biophysical Journal. 22 (3): 507–512. Bibcode:1978BpJ....22..507K. doi:10.1016/s0006-3495(78)85503-9. PMC 1473482. PMID 667299.
Baker DE (November 2013). "Breakthrough Drug Approval Process and Postmarketing ADR Reporting". Hospital Pharmacy. 48 (10): 796–798. doi:10.1310/hpj4810-796. PMC 3859287. PMID 24421428.
Solari A, Uitdehaag B, Giuliani G, Pucci E, Taus C (2002). "Aminopyridines for symptomatic treatment in multiple sclerosis". The Cochrane Database of Systematic Reviews (4): CD001330. doi:10.1002/14651858.CD001330. PMC 7047571. PMID 12804404.

nytimes.com

Tavernise S (February 17, 2016). "F.D.A. Deals Setback to Catalyst in Race for Drug Approval". New York Times.
Tavernise S (December 22, 2015). "Patients Fear Spike in Price of Old Drugs". New York Times.

pemagazine.fr

Chapelle FX (November 4, 2008). "OPi ou comment construire une biopharma en moins de dix ans - Private Equity Magazine". Private Equity Magazine (in French).

pharmaceutical-technology.com

"Huxley Acquisition Lands Biomarin New LEMS Treatment". Pharmaceutical Technology. October 28, 2009. Archived from the original on September 17, 2020. Retrieved January 14, 2017.

raredr.com

Radke J (October 29, 2014). "Catalyst Using the Expanded Access Program to Conduct Phase IV Study with LEMS Patients". Rare Disease Report. Archived from the original on June 13, 2018. Retrieved June 13, 2018.

sciencemag.org

blogs.sciencemag.org

Lowe D (October 21, 2013). "Catalyst Pharmaceuticals And Their Business Plan". In the Pipeline.

semanticscholar.org

api.semanticscholar.org

Argov Z (October 2009). "Management of myasthenic conditions: nonimmune issues". Current Opinion in Neurology. 22 (5): 493–497. doi:10.1097/WCO.0b013e32832f15fa. PMID 19593127. S2CID 10408557.
Nicholl DJ, Hilton-Jones D, Palace J, Richmond S, Finlayson S, Winer J, et al. (November 2010). "Open letter to prime minister David Cameron and health secretary Andrew Lansley". BMJ. 341: c6466. doi:10.1136/bmj.c6466. PMID 21081599. S2CID 24929143.
Hawkes N, Cohen D (November 2010). "What makes an orphan drug?". BMJ. 341: c6459. doi:10.1136/bmj.c6459. PMID 21081607. S2CID 2486975.
Vedeler CA, Antoine JC, Giometto B, Graus F, Grisold W, Hart IK, et al. (July 2006). "Management of paraneoplastic neurological syndromes: report of an EFNS Task Force". European Journal of Neurology. 13 (7): 682–690. doi:10.1111/j.1468-1331.2006.01266.x. PMID 16834698. S2CID 27161239.
Burns TM, Smith GA, Allen JA, Amato AA, Arnold WD, Barohn R, et al. (February 2016). "Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine". Muscle & Nerve. 53 (2): 165–168. doi:10.1002/mus.25009. PMID 26662952. S2CID 46855617.
Sedehizadeh S, Keogh M, Maddison P (2012). "The use of aminopyridines in neurological disorders". Clinical Neuropharmacology. 35 (4): 191–200. doi:10.1097/WNF.0b013e31825a68c5. PMID 22805230. S2CID 41532252.

statnews.com

Silverman E (April 5, 2016). "A family-run drug maker tries to stay afloat in the Shkreli era". STAT News.

tga.gov.au

"Ruzurgi APMDS". Therapeutic Goods Administration (TGA). 24 September 2021. Retrieved 30 September 2021.
"Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 12 May 2022. Retrieved 13 May 2022.

web.archive.org

"Firdapse Summary of Product Characteristics" (PDF). EMA. February 11, 2010. Archived from the original (PDF) on June 20, 2018. Retrieved November 28, 2015. See EMA Index page, product tab Archived 2018-09-20 at the Wayback Machine
"Public summary of opinion on orphan designation" (PDF). EMA. June 14, 2010. Archived from the original (PDF) on June 21, 2018. Retrieved January 14, 2017.
"Assessment report: Zenas" (PDF). EMA CHMP committee. 2009. Archived from the original (PDF) on 2018-09-20. Retrieved 2015-05-28.
"Huxley Acquisition Lands Biomarin New LEMS Treatment". Pharmaceutical Technology. October 28, 2009. Archived from the original on September 17, 2020. Retrieved January 14, 2017.
Radke J (October 29, 2014). "Catalyst Using the Expanded Access Program to Conduct Phase IV Study with LEMS Patients". Rare Disease Report. Archived from the original on June 13, 2018. Retrieved June 13, 2018.
"Orrphan designation congenital myasthenic syndromes". FDA. Archived from the original on July 26, 2015.

who.int

"International Nonproprietary Names for Pharmaceutical Substances (INN) Recommended INN: List 58" (PDF). WHO Drug Information. 21 (3). 2007.

yixiblog.wordpress.com

"Jacobus Pharmaceuticals". Drug R&D Insight. April 25, 2015.